Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 254 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $84.10, for a total value of $21,361.40. Following the completion of the transaction, the president now directly owns 1,442,357 shares in the company, valued at $121,302,223.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Stephen Hoge also recently made the following trade(s):
- On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00.
- On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00.
- On Wednesday, May 29th, Stephen Hoge sold 341 shares of Moderna stock. The stock was sold at an average price of $144.50, for a total value of $49,274.50.
Moderna Stock Up 5.3 %
Shares of MRNA opened at $86.62 on Friday. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The firm has a market capitalization of $33.20 billion, a P/E ratio of -5.53 and a beta of 1.67. The company has a 50-day simple moving average of $117.52 and a 200-day simple moving average of $113.92. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.91 and a current ratio of 4.09.
Wall Street Analyst Weigh In
Several research firms recently issued reports on MRNA. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their price target on Moderna from $96.00 to $88.00 and set a “neutral” rating on the stock in a research report on Thursday. Barclays reduced their price target on Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday, August 1st. Finally, Evercore ISI reiterated an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus price target of $124.07.
Get Our Latest Analysis on MRNA
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Moderna by 22.6% in the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after purchasing an additional 6,248,623 shares in the last quarter. Norges Bank acquired a new position in shares of Moderna during the fourth quarter valued at $347,565,000. Wellington Management Group LLP boosted its holdings in Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after acquiring an additional 1,614,460 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Moderna by 42.9% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after purchasing an additional 463,960 shares during the last quarter. Finally, Matrix Capital Management Company LP acquired a new position in Moderna during the 4th quarter valued at about $45,150,000. Institutional investors own 75.33% of the company’s stock.
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Stories
- Five stocks we like better than Moderna
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Stocks Options Traders Safeguarded with Puts After Market Jolt
- Manufacturing Stocks Investing
- Michael Burry’s Alibaba Bet and the Broader Market Implications
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.